Atorvastatin and cardiovascular risk in the elderly – patient considerations

Atorvastatin and cardiovascular risk in the elderly – patient considerations

Subroto Acharjee, Francine K WeltyDivision of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: Elderly individuals are at increased risk of coronary heart disease (CHD) and account for a majority of CHD deaths. Several clinical trials have assessed the beneficial effects of...

Full description

Bibliographic Details
Main Authors:	Subroto Acharjee, Francine K Welty
Format:	Article
Language:	English
Published:	Dove Medical Press 2008-06-01
Series:	Clinical Interventions in Aging
Online Access:	https://www.dovepress.com/atorvastatin-and-cardiovascular-risk-in-the-elderly-ndash-patient-cons-peer-reviewed-article-CIA

Similar Items

Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
by: R. S. Karpov, et al.
Published: (2009-08-01)

Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
by: Madhuri Devabhaktuni, et al.
Published: (2009-04-01)

Atorvastatin in the secondary prevention of cardiovascular diseases
by: N. A. Vaulin
Published: (2014-12-01)

Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients
by: Yi-Cong Ye, et al.
Published: (2015-01-01)

Influence of atorvastatin therapy on biological markers and cardiovascular risk in patients with chronic lymphocytic leukemia in remission
by: B.B. Samura
Published: (2019-02-01)

Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006)
by: S. A. Shalnova, et al.
Published: (2010-12-01)

Monacolin and atorvastatin in cardiovascular prevention – an attempt at positioning
by: Marcin Barylski
Published: (2017-03-01)

Mechanistic insights into the acute cardiovascular protection of Atorvastatin
by: Shakkotai, P. V.
Published: (2011)

Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases
by: S A Smakotina, et al.
Published: (2015-09-01)

Does atorvastatin work more effectively than biguanides in reducing cardiovascular risk factors?
by: Afshan Siddiq, et al.
Published: (2011-01-01)

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US
by: Marrett E, et al.
Published: (2014-04-01)

Atorvastatin therapy modulates telomerase activity in patients free of atherosclerotic cardiovascular diseases
by: Irina Strazhesko, et al.
Published: (2016-09-01)

Atorvastatin and simvastatin in clinical management of high-risk patients
by: S. A. Shalnova, et al.
Published: (2009-02-01)

Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
by: Renate M. Hoogeveen, et al.
Published: (2021-02-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

Coping, schemas, and cardiovascular risks – study protocol
by: Slepecky M, et al.
Published: (2017-10-01)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
by: Kuecker CM, et al.
Published: (2016-02-01)

Sudden rhabdomyolysis in an elderly patient after single atorvastatin dose: The need for early and frequent creatine kinase monitoring in high-risk patients
by: Min Xiao, et al.
Published: (2020-07-01)

Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
by: Jaecheol Moon, et al.
Published: (2020-01-01)

Patient considerations in metastatic colorectal cancer – role of panitumumab
by: Rogers JE
Published: (2017-04-01)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
by: Kothari M, et al.
Published: (2015-08-01)

Patient considerations in the management of toe onychomycosis – role of efinaconazole
by: LaSenna CE, et al.
Published: (2015-06-01)

Effect of atorvastatin combine with aspirin on flammatory factors, endothelial function and the cardiovascular complications with diabetic patients
by: Hong Wang, et al.
Published: (2016-03-01)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
by: Sofía Perez-Calahorra, et al.
Published: (2019-12-01)

Managing infertility with the follitropin alfa prefilled pen injector – patient considerations
by: Bühler K
Published: (2015-06-01)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
by: Cruciani M, et al.
Published: (2015-02-01)

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
by: Gandhi SK, et al.
Published: (2012-01-01)

Antioxidant status of atorvastatin in hypercholesterolemic patients
by: Nasar Mohammad A., et al.
Published: (2009-01-01)

Antioxidant status of atorvastatin in hypercholesterolemic patients
by: MOHAMMAD A. NASAR, et al.
Published: (2009-09-01)

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
by: Bodiford A, et al.
Published: (2015-09-01)

Cardiovascular Risk and Statin Therapy Considerations in Women
by: Gina Gheorghe, et al.
Published: (2020-07-01)

Comprehensive cardiovascular risk management – what does it mean in practice?
by: Leif Erhardt, et al.
Published: (2007-11-01)

Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems – enhancement of oral bioavailability
by: Hashem FM, et al.
Published: (2015-06-01)

Analysis of risk factors in patients with severe chronic kidney disease. The role of atorvastatin.
by: Holmberg, Benny
Published: (2013)

Atorvastatin preoperative use in patients with coronary risk factors in major noncardiac surgery.
by: Alberto Labrada Despaigne, et al.
Published: (2016-07-01)

Endothelial function in a cardiovascular risk population with borderline ankle–brachial index
by: Syvänen K, et al.
Published: (2011-02-01)

Myopathy in patients taking atorvastatin: A pilot study
by: K Manoj, et al.
Published: (2017-01-01)

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
by: Salim Ahmed, et al.
Published: (2008-06-01)

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia
by: Selim Ahmed, et al.
Published: (2008-04-01)

Impact of cardiovascular risk factors on carotid intima–media thickness: sex differences
by: Łoboz-Rudnicka M, et al.
Published: (2016-05-01)